Please: Login/Register

The Latest Edition of "Eyes on malaria" magazine will be out very soon!! | CALL FOR ARTICLES: AMMREN is inviting journalists / writers / scientists interested in reporting on malaria to send articles for publication in its international magazine “Eyes on Malaria” and for posting on its website. Please contact the AMMREN Secretariat for more details click here. Enjoy your stay!. Volunteers and interns urgently needed to work with an NGO working in the area of malaria and health. Apply through - ammren1@gmail.com / ammren1@yahoo.com. Journalists interested in reporting on and writing articles on health issues should please reply through this email: ammren1@gmail.com

ANNOUNCEMENTS:::

TIPS ON MALARIA

  • HOW CAN MOSQUITOES BE CONTROLLED?

    Mosquitoes around the home can be reduced significantly by minimizing the amount of standing water available for mosquito breeding. Residents are urged to reduce standing water around the home in a variety of ways.

  • HOW CAN I PROTECT MYSELF FROM MOSQUITO-BORN DISEASES?

    The best way is to avoid being bitten by mosquitoes.This can be accomplished using personal protecting  while outdoors when mosquitoes are present. Treated bed nets should be used sleeping. Mosquito repellent should be used when outdoor.

  • WHO ARE AT RISK?


    Nearly half of the world’s population is at risk of getting malaria. Pregnant women are particularly at risk of malaria. Children under 5 years are at high risk of malaria.
     

MAGAZINE EDITIONS

  • Sixth Edition

  • First Edition

  • Second Edition

  • Third Edition

  • Fourth Edition

  • Fifth Edition

  • Seventh Edition

  • Eighth Edition

  • Ninth Edition

  • Special Edition

  • INESS Edition

  • Tenth Edition

  • INDEPTH Edition

  • Eleventh Edition

  • Twelfth Edition

  • Special Edition

  • Special Edition

  • March Edition

UGANDA: COST OF ANTI-MALARIA DRUGS TOO HIGH

 
Access to anti-malaria drugs remains elusive as retailers in privately owned health facilities continue to charge exorbitant prices in spite of government subsidies, a new study has revealed.
 
A report on monitoring availability and prices for-co-paid artemisinin combination therapies (ACTs) in the private sector in Uganda revealed that while 87 percent of co-paid malaria drugs are available in the market, however, the final retail price is prohibitive for the rural population.
 
For instance, while the manufacturers charge a median price of UShs900 ($0.25) for a six by four pack, which is a complete dosage, wholesalers’ offer it at median cost of Ush2,000 ($0.55) and the prices double to a median of Ushs4,000 ($1.11) at retail. The six-by-four pack is the most preferred malaria treatment.
 
"We have already paid 70 percent of the costs of the drugs to the manufacturers, so we do not expect the prices to be too high at retail. The public should report facilities that are charging high prices for branded ACT," said Jimmy Opigo, programme manager at the Ministry of Health.
 
“Half of our population gets malaria treatment from private facilities, but they are faced with price barriers. Yet if they delay treatment, the disease goes into a severe form; so, we need to bring the prices down," added Dr Opigo.
 
The private sector is being subsidised with the aim of increasing access to affordable anti-malaria drugs after findings showed that half of the population gets treatment from the private sector, with the rural population paying a much higher price for co-paid ACTs.
 
Although the ACTs are free in public health facilities, a significant number of people are compelled to go to private facilities owing to frequent stock-outs, long queues and distance to government facilities said Denis Kibira, executive director, HEPS-Uganda, a non-governmental organisation that conducted the study.
 
The study was conducted in six regions -- Central, Northern, West Nile, Western, South-western and Eastern Uganda -- involving 477 private for profit facilities. The study was done between November and December 2016.
 
Exorbitant prices are one of the factors that prompted the government to shift malaria treatment from chloroquine and fansidar to ACTs, Dr Opigo added.